Table. 4.

Risk factor analysis of graft failure

Risk factor Univariable Multivariablea)


HR (95% CI) P-value HR (95% CI) P-value
Recipient
Age 0.980 (0.964–0.996) 0.015 0.971 (0.954–0.987) 0.001
Male 1.225 (0.871–1.722) 0.243
BMI 1.061 (1.012–1.112) 0.015 1.055 (1.007–1.107) 0.025
DM 1.692 (1.094–2.616) 0.018 1.962 (1.225–3.141) 0.005
HTN 0.729 (0.048–1.118) 0.148
Underlying kidney disease 2b) 0.024
DM nephropathy ref
GN (IgA, FSGS, others) 0.481 (0.285–0.810) 0.006
ADPCK 0.701 (0.288–1.709) 0.435
Hypertensive 0.632 (0.362–1.104) 0.107
Other and UK 0.465 (0.287–0.755) 0.002
Dialysis duration 0.962 (0.879–1.054) 0.408
Pre-emptive KTc) 0.942 (0.621–1.429) 0.778
HLA mismatch 1.027 (0.920–1.146) 0.641
DSA positive 1.071 (0.263–4.352) 0.924
Induction agent 0.575
No agent ref
Basiliximab 1.247 (0.805–1.932) 0.323
r-ATG 1.545 (0.618–3.864) 0.352
r-ATG+rituximab 1.656 (0.512–5.361) 0.400
Maintenance regimen 0.871
CsA+MMF+PD ref
FK+MMF+PD 0.914 (0.643–1.293) 0.604
Sirolimus or everolimus combination 1.321 (0.369–4.725) 0.669
Otherd) 1.821 (0.108–30.69) 0.677
Donor
Male 0.880 (0.631–1.226) 0.449
BMI 1.036 (0.986–1.088) 0.164
DM 1.725 (0.241–12.365) 0.588
HTN 0.569 (0.079–4.078) 0.575
Cr 0.739 (0.254–2.152) 0.579
Older donor groupe) 2.320 (1.081–4.978) 0.031 2.352 (1.093–5.061) 0.029

HR, hazard ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; GN, glomerulonephritis; IgA, immunoglobulin A; FSGS, focal segmental glomerulosclerosis; ADPCK, autosomal dominant polycystic kidney disease; UK, unknown; KT, kidney transplantation; HLA, human leukocyte antigen; DSA, donor specific anti-HLA antibodies; r-ATG, rabbit anti-thymocyte globulin; CsA, cyclosporin A; MMF, mycophenolate mofetil; PD, prednisone; FK, tacrolimus; Cr, creatinine.

a)Variables with a P-value of less than 0.1 in the univariable analysis were included in the multivariable analysis; b)Underlying kidney disease 2 and R DM have a high relationship; if both variables have P<0.1, only recipient DM was included in multivariable analysis; c)Pre-emptive KT was defined as kidney transplantation after dialysis duration less than 30 days; d)Other maintenance regimen refers to FK+mizoribine+PD; e)Reference is younger donor group, which is group of KT donor less than 60 years old.

Korean J Transplant 2021;35:238~246 https://doi.org/10.4285/kjt.21.0020
© Korean Journal of Transplantation